Beauty Health (NASDAQ:SKIN) Given New $1.65 Price Target at TD Cowen

Beauty Health (NASDAQ:SKIN) had its price objective lifted by TD Cowen from $1.50 to $1.65 in a research note issued to investors on Wednesday morning, Marketbeat reports. They currently have a hold rating on the stock.

Several other research analysts also recently commented on the stock. Wall Street Zen downgraded shares of Beauty Health from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beauty Health in a research report on Friday, October 31st. Jefferies Financial Group reiterated a “hold” rating and issued a $1.60 price target on shares of Beauty Health in a report on Wednesday, January 14th. Finally, Zacks Research cut Beauty Health from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 19th. One equities research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $2.40.

Beauty Health Trading Up 6.9%

Shares of NASDAQ SKIN opened at $1.54 on Wednesday. Beauty Health has a fifty-two week low of $0.78 and a fifty-two week high of $2.69. The company has a debt-to-equity ratio of 5.53, a quick ratio of 4.07 and a current ratio of 4.98. The company has a market cap of $196.35 million, a price-to-earnings ratio of -7.00 and a beta of 1.16. The business’s 50 day moving average price is $1.44 and its 200-day moving average price is $1.70.

Beauty Health (NASDAQ:SKIN) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). Beauty Health had a negative net margin of 3.87% and a negative return on equity of 19.70%. The business had revenue of $70.66 million for the quarter, compared to analysts’ expectations of $68.33 million. On average, sell-side analysts expect that Beauty Health will post -0.25 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Mirabella Financial Services LLP raised its position in shares of Beauty Health by 21.3% in the 3rd quarter. Mirabella Financial Services LLP now owns 15,596,277 shares of the company’s stock worth $31,037,000 after acquiring an additional 2,734,728 shares in the last quarter. Woodline Partners LP grew its stake in Beauty Health by 255.9% in the third quarter. Woodline Partners LP now owns 5,930,027 shares of the company’s stock valued at $11,801,000 after purchasing an additional 4,263,997 shares during the last quarter. Geode Capital Management LLC raised its holdings in Beauty Health by 27.5% in the second quarter. Geode Capital Management LLC now owns 2,302,784 shares of the company’s stock worth $4,399,000 after purchasing an additional 496,963 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Beauty Health by 11.8% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,210,898 shares of the company’s stock valued at $2,410,000 after buying an additional 127,994 shares during the last quarter. Finally, Soleus Capital Management L.P. bought a new stake in shares of Beauty Health in the 2nd quarter valued at about $1,910,000. 93.26% of the stock is currently owned by hedge funds and other institutional investors.

About Beauty Health

Beauty Health Company (NASDAQ: SKIN) is a U.S.-based consumer wellness and beauty enterprise that integrates device-based and product-based offerings across skin, body and hair wellness categories. The company operates a portfolio of established brands that blend professional and at-home solutions, focusing on innovative formulations and technologies to address a range of beauty and self-care needs. Through its proprietary e-commerce platforms and strategic retail partnerships, Beauty Health seeks to deliver premium experiences and tangible results to a global customer base.

Beauty Health’s brand portfolio includes Sol de Janeiro, known for its award-winning Brazilian Bum Bum Cream body care collection; Elemis, a U.K.-originated professional skin care line distributed in spas and skincare clinics; NuFACE and Dermaflash, two at-home beauty device brands specializing in microcurrent facial toning and gentle exfoliation respectively; and Nutrafol, a legal-strength hair wellness supplement clinically designed to support hair growth.